Skip to content
Medical Health Aged Care, Political

Media Alert – Community Health in Focus: Community Health First Launches 2025 Impact Report

Community Health First < 1 mins read

What:  

Minister for Health, Hon Mary-Anne Thomas will speak at the launch of Community Health First 2025 Impact Report. The report showcases the critical role of community health in delivering equitable, accessible healthcare across Victoria. 

When: 

Tuesday 14 October 2025 

3:00 pm – 4.30 pm  

Where: 

South Library

Parliament House of Victoria 

Spring St, East Melbourne

Who:

  • Minister for Health, Hon. Mary-Anne Thomas MP
  • Anna Robinson, Chair Community Health First, and CEO Access Health and Community
  • Sean Duffy, CEO Ballarat Community Health 

Why: 

  • More Victorians than ever are turning to community health with new data revealing an 11% annual growth in demand. As the cost of living continues to climb, people are delaying or avoiding mainstream healthcare.  

  • Community health provides a vital service: affordable, local and tailored care.

  • This launch unveils compelling new evidence on the cost effectiveness of treating people in community settings, close to home and out of hospitals, including new and innovative programs tackling chronic disease that are helping people better manage their condition, saving our health system millions of dollars per year. 

  Media Opportunities: 

  • Interview opportunities with Community Health First spokesperson, Anna Robinson and community member panellists 

  • Photo and filming opportunities 

  • Media kit available on request 

 RSVP required to attend event. 


About us:

Community Health First unites all 22 registered independent community health services with one shared goal – improving the health, wellbeing and quality of life for all Victorians.


Contact details:

Jo French 

Media and Communications Advisor - Community Health First

Mob: 0423 811 048

Email: [email protected]

 

Media

More from this category

  • Energy, Political
  • 08/12/2025
  • 11:11
Greenpeace Australia Pacific

Labor must stop propping up dirty gas and support industry to decarbonise

SYDNEY, Monday 8 December 2025 — Greenpeace Australia Pacific has warned the Albanese government against plans to subsidise gas for industrial users, saying it should instead be supporting industry todecarbonise. Media reports today that Labor is weighing up an intervention to start bulk-buying gas and selling it at discounted rates to industrial users, comes as the government is expected to announce an East Coast gas reservation policy in the coming weeks. Greenpeace says the intervention would be at odds with Australia’s commitment to phase out inefficient fossil fuel subsidies, including under the Glasgow Climate Pact and the Belém Declaration on…

  • Medical Health Aged Care
  • 08/12/2025
  • 10:11
BeOne Medicines Ltd.

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL Sonrotoclax in combination with BRUKINSA demonstrated rapid…

  • Contains:
  • Medical Health Aged Care
  • 08/12/2025
  • 09:40
Miltenyi Biomedicine

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease featuresA 12-day manufacturing time resulted in a vein-to-vein time of 14-16 days, reducing the likelihood for bridging therapy.BERGISCH GLADBACH, Germany, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Miltenyi Biomedicine today announced results from the pivotal DALY 2-EU trial evaluating the efficacy and safety of zamtocabtagene autoleucel (zamto-cel) compared with standard chemoimmunotherapy (R-GemOx or Pola-BR) in patients with…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.